Intensity of metastasis screening and survival outcomes in patients with breast cancer

Jong-Ho Cheun(Seoul National University), Hyeong‐Gon Moon(Seoul National University), Ji Gwang Jung(Seoul National University Hospital), Eun-Shin Lee(Seoul National University Hospital), Seock‐Ah Im(Seoul National University), Dong‐Young Noh(Seoul National University), Tae‐Yong Kim(Seoul National University), Kyung-Hun Lee(Seoul National University), Jiyoung Rhu(Catholic University of Korea), Wonshink Han(Seoul National University), Han‐Byoel Lee(Seoul National University Hospital)
Unknown
March 11, 2020
10.21203/rs.3.rs-16848/v1
Cited by 1

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k